Background: The National Early Warning Score (NEWS/NEWS 2) has been adopted across the National Health Service (NHS) in the U.K. as a method of escalating care for deteriorating patients. Intensive Care Unit (ICU) resources are limited and in high demand, with patient discharge a focal point for managing resources effectively. There are currently no universally accepted methods for assessing discharge of patients from an ICU, which can cause premature discharges and put patients at risk of subsequent deterioration, readmission to ICU or death.
Methods: We tested the ability of the NEWS to discriminate patients within 24h of admission to an ICU in a U.S. hospital during 2001-2012, by their end discharge location: home; hospital ward; nursing facility; hospice and death. The NEWS performance was compared across five different ICU specialties, using the area under the receiver operating characteristic (AUROC) curve and a large vital signs database (n=2,723,055) collected from 28,523 critical care admissions.
Results: The NEWS AUROC (95% CI) at 24h following admission: all patients 0.727 (0.709-0.745); Coronary Care Unit (CCU) 0.829 (0.821-0.837); Cardiac Surgery Recovery Unit (CSRU) 0.844 (0.838-0.850); Medical Intensive Care Unit (MICU) 0.778 (0.767-0.791); Surgical Intensive Care Unit (SICU) 0.775 (0.762-0.788); Trauma Surgical Intensive Care Unit (TSICU) 0.765 (0.751-0.773).
Conclusions: The NEWS has reasonable discrimination for any ICU patient's discharge location. The NEWS has greater ability to discriminate patients in the Coronary Care Unit (CCU) and Cardiac Surgery Recovery Unit (CSRU) compared to other ICU specialties. The NEWS has the real potential to be applied within a universal discharge planning tool for ICU, improving patient safety at the point of discharge.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6729008 | PMC |
http://dx.doi.org/10.1186/s12889-019-7541-3 | DOI Listing |
JAMA Oncol
January 2025
Department of Paediatric Haematology, Oncology and Immunodeficiency, University Hospital Justus-Liebig University Giessen, Giessen, Germany.
Importance: The current standard-of-care salvage therapy in relapsed/refractory classic Hodgkin lymphoma (cHL) includes consolidation high-dose chemotherapy (HDCT)/autologous stem cell transplant (aSCT).
Objective: To investigate whether presalvage risk factors and fludeoxyglucose-18 (FDG) positron emission tomography (PET) response to reinduction chemotherapy can guide escalation or de-escalation between HDCT/aSCT or transplant-free consolidation with radiotherapy to minimize toxic effects while maintaining high cure rates.
Design, Setting, And Participants: EuroNet-PHL-R1 was a nonrandomized clinical trial that enrolled patients younger than 18 years with first relapsed/refractory cHL across 68 sites in 13 countries in Europe between January 2007 and January 2013.
Eur J Pediatr
January 2025
Alliance of Dutch Burn Care, Burn Center, Red Cross Hospital, PO Box 1074, 1940 EB, Beverwijk, the Netherlands.
Unlabelled: Knowledge about trends and epidemiology of pediatric burns is useful to identify patterns, to advance medical research, and to design prevention programs and resource allocation. The aim of this study is to describe the epidemiology and trends of pediatric burns between 2009 and 2022 in the three Dutch burn centers. A secondary objective of this study is to evaluate the influence of the COVID-19 pandemic on the pattern of pediatric burns.
View Article and Find Full Text PDFAm J Manag Care
December 2024
Department of Health Outcomes Research and Policy, Auburn University Harrison College of Pharmacy, 4306D Walker Building, Auburn University, Auburn, AL 36849-5506. Email:
Objectives: This study evaluated the uptake and costs of 3 biosimilars among Medicare and Medicaid populations for 2019 to 2022: rituximab-abbs (Truxima), rituximab-pvvr (Ruxience), and rituximab-arrx (Riabni).
Study Design: A retrospective, descriptive study.
Methods: Using the annually aggregated, product-level utilization and cost data of biologic and biosimilar rituximab products from CMS drug spending data, total claims and costs (reimbursement and out of pocket) for all rituximab products were identified and extracted from Medicare Part B, Medicare Part D, and Medicaid.
Ann Emerg Med
January 2025
Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA.
Study Objective: Physician experiences with new care models like the virtual observation unit in emergency departments (EDs) can offer important insights. Virtual observation unit leverages telehealth, remote monitoring, and mobile integrated health to enable home-based ED-level care. We explored physicians' experience with delivering care in the virtual observation unit and perceived effect of this new model.
View Article and Find Full Text PDFInfect Immun
December 2024
Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, the Thoracic Diseases Research Unit, Mayo Clinic College of Medicine, Rochester, Minnesota, USA.
pneumonia (PJP) remains a significant cause of morbidity and mortality during AIDS. In AIDS, the absence of CD4 immunity results in exuberant and often fatal PJP. In addition, organism clearance requires a balanced macrophage response since excessive inflammation promotes lung injury and respiratory failure.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!